Dr. Paul I. Lammers M.D. serves as Lead Independent Director of the Company. Since January 2018, Dr. Lammers has served as the president and chief executive officer of Triumvira Immunologics, an immunotherapy company. Prior to joining Triumvira Immunologics, Dr. Lammers served as the president, chief executive officer, and director of Mirna Theraputics, now Synlogic Inc. (Nasdaq: SYBX), an oncology company from November 2009 to August 2017, the president of Repros Theraputics, a biopharmaceutical company, from February 2009 to October 2009 and the chief medical officer of EMD Serono Inc. a division of Merk KgaA, a biopharmaceutical company from 2002 to 2008. Additionally, between 1992 and 2002, Dr. Lammers served in various executive or management roles at BioCyte Theraputics, Inc., a biopharmaceutical company, Zonagen, Inc., a biopharmaceutical company, Hoechst Marion Roussel, Inc. (now Aventis Pharmaceuticals Inc.), a pharmaceutical company, Organon Inc., a pharmaceutical company, Organon International, a pharmaceutical company. Dr. Lammers earned a M.S. in Biology and Reproductive Endocrinology from Radboud University in the Netherlands, and an M.D. from Radboud University.
Paul's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum, and Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: